P. Benn

发表

Chlamydia trachomatis and Neisseria gonorrhoeae infection and the sexual behaviour of men who have sex with men

G. Ridgway, A. Copas, C. Carder, 2006, Sexually Transmitted Infections.

Home delivery of medication – the role of a patient information leaflet on maximising service uptake

S Edwards, L. Waters, J. Minton, 2014, International journal of STD & AIDS.

UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure

D. Hawkins, Mike Jones, A. Pozniak, 2006, International journal of STD & AIDS.

Comparison of two interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in testing for latent tuberculosis infection among HIV-infected adults

M. Young, S. Morris-Jones, Rf Miller, 2013, International journal of STD & AIDS.

UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011)

D. Hawkins, Mike Jones, A. Pozniak, 2006, International journal of STD & AIDS.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

S. Swindells, C. Orrell, Kimberly Smith, 2020, The Lancet.

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

S. Swindells, Kimberly Smith, H. Crauwels, 2021, AIDS (London, England).

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

S. Swindells, Kimberly Smith, E. Overton, 2021, The Patient - Patient-Centered Outcomes Research.

Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)

D. Hawkins, A. Copas, A. Milinkovic, 2017, The Journal of antimicrobial chemotherapy.

Current perspectives in HIV post-exposure prophylaxis

L. Waters, B. Sultan, P. Benn, 2014, HIV/AIDS.

Postexposure prophylaxis for HIV following sexual exposure

T. Barber, P. Benn, 2010, Current opinion in HIV and AIDS.

Is the recall of men who have sex with men (MSM) diagnosed as having bacterial sexually transmitted infections (STIs) for re-screening a feasible and effective strategy?

D. Harte, D. Mercey, P. Benn, 2011, Sexually Transmitted Infections.

Prevalence of vitamin D deficiency in HIV-positive, antiretroviral treatment-naïve patients in a single centre study

A. Grant, K. Gedela, S. Edwards, 2014, International journal of STD & AIDS.

The clinical manifestations of anorectal infection with lymphogranuloma venereum (LGV) versus non-LGV strains of Chlamydia trachomatis: a case–control study in homosexual men

A. Copas, H. Ward, C. Carder, 2007, International journal of STD & AIDS.

Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1

Geoffrey Scott, D. Mercey, P. Benn, 2001, The Lancet.

Enhancing patient safety with an electronic results checking system in a large HIV outpatient service.

R. Miller, R. Ferrand, S. Edwards, 2013, British journal of hospital medicine.

Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials

C. Harrington, P. Patel, P. Benn, 2022, Journal of acquired immune deficiency syndromes.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Kimberly Smith, H. Crauwels, E. Overton, 2021, The lancet. HIV.

Changes in the provision of post-exposure prophylaxis for HIV after sexual exposure following introduction of guidelines and publicity campaigns

A. Copas, M. Fisher, I. Reeves, 2008, International journal of STD & AIDS.

Does using self-completed sexual history questionnaires in HIV-positive men who have sex with men affect clinical outcomes?

S. Edwards, G. Brough, P. Benn, 2008, International journal of STD & AIDS.

Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens

A. Schwenk, F. Grimson, Stephen Taylor, 2021, International journal of STD & AIDS.

Chlamydia trachomatis

C. Carder, D. Mercey, P. Benn, 2006, Sexually Transmitted Infections.

Improvements in facial lipoatrophy at 48 weeks following substitution of a thymidine analogue with tenofovir (TDF) or abacavir (ABC): a randomized, open-label study in people with lipoatrophy and virological suppression on HAART

Sauret, C. Sabin, G. Moyle, 2005 .

The “3 in 1” Study: Pooling Self-Taken Pharyngeal, Urethral, and Rectal Samples into a Single Sample for Analysis for Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in Men Who Have Sex with Men

A. Copas, A. Robinson, A. Robinson, 2015, Journal of Clinical Microbiology.

Test of cure study: a feasibility study to estimate the time to test of cure (TOC) for Neisseria gonorrhoeae and Chlamydia trachomatis infections

G. Schembri, C. Ison, S. Alexander, 2020, Sexually Transmitted Infections.

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

M. Marzinke, R. Landovitz, W. Spreen, 2022, British journal of clinical pharmacology.

HIV and postexposure prophylaxis.

M. Fisher, P. Benn, 2008, Clinical medicine.

Polypharmacy and potential drug–drug interactions for people with HIV in the UK from the Climate‐HIV database

A. Schwenk, F. Grimson, S. Taylor, 2020, HIV medicine.

Devolving of statin prescribing to general practitioners for HIV-infected patients receiving antiretroviral therapy

R. Miller, J. Minton, S. Edwards, 2009, International journal of STD & AIDS.

Multicentre RCT and economic evaluation of a psychological intervention together with a leaflet to reduce risk behaviour amongst men who have sex with men (MSM) prescribed post-exposure prophylaxis for HIV following sexual exposure (PEPSE): A protocol

C. Abraham, A. Miners, Helen E. Smith, 2012, BMC Infectious Diseases.

Stop routine CD4 monitoring in HIV-infected patients with fully suppressed virus and CD4 >=350 cells/ml.

L. Waters, G. Whitlock, S. Edwards, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Routine detection and management of neurocognitive impairment in HIV-positive patients in a UK centre

L. Haddow, H. Manji, R. Gilson, 2013, International journal of STD & AIDS.

Role of darunavir in the management of HIV infection

P. Benn, R. Lascar, 2009 .

Postexposure prophylaxis for HIV following sexual exposure

T. Barber, P. Benn, 2010, Current Opinion in HIV and AIDS.

A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937

P. Benn, Veronica Bainbridge, M. Gartland, 2023, Pharmacology research & perspectives.